{
  "docId": "019de070-9f9d-7718-acb6-17a3db6270ac",
  "docSlug": "7a58434f86a94bb0eba92fad9f688c31",
  "documentTitle": "23andMe | SPAC Presentation Deck | 47 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 47,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a three-step process flow (Market -> Validation -> Mechanism) to justify the CD96 program.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-9f9d-7718-acb6-17a3db6270ac/33",
  "deckHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac",
  "deckJsonHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac.json",
  "deckAnchorHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.48
      },
      "kind": "chart",
      "text": "I/O genetic signature showing opposing effects on autoimmune and cancer phenotypes",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84725985-c0e2-4b5d-a185-c7c54133a4d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.71,
        "y": 0.48
      },
      "kind": "image",
      "text": "Diagram of CD96, CD226, TIGIT signaling pathway between APC/Tumor cell and T cell/NK cell",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0d4324c-916e-4c37-8b76-8c95da1ddf05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.29,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "list",
      "text": "Large I/O market with over $41B expected in 2021 sales",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63091d7d-fef1-456a-bf35-0a00f4225508",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "GSK'608 (anti-CD96) is progressing through a Phase 1 multi-ascending dose trial in patients with advanced solid tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8e31896-f0eb-49b1-a628-df329c05adb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma historical and forecast estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "708c7640-6e3e-40ef-97e5-4eac51907f8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "table",
      "text": "KEYTRUDA $17.0B, OPDIVO $7.9B, YERVOY $1.8B",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4590ef0-3b9c-42ca-aec2-2e60e1310d96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.76,
        "x": 0.12,
        "y": 0.05
      },
      "kind": "title",
      "text": "Our Lead CD96 Program Was Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4966c729-d966-4a0a-8fd3-ee3ee64436ba",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "26a68f91-4b6f-4574-affb-965c04eb6371",
      "evidence": "Three-column flow from market to mechanism",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 47,
      "from": 31,
      "beatId": "c6e32088-5ffd-4801-8f4d-73b03f070b9a",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Ultimate Achievement",
      "beatSlug": "rags-to-riches-ultimate-achievement",
      "evidence": "The deck concludes with 23andMe's financials, growth prospects, and transaction overview",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 31,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "948c0ef0-9704-4173-be05-25230dbef10f",
      "evidence": "The deck presents 23andMe's lead CD96 program and pipeline across multiple therapeutic areas",
      "position": 2,
      "objective": "The potential for 23andMe's therapeutics discovery efforts",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}